Heart and kidney disease are closely linked, as individuals with chronic kidney disease (CKD) face a significantly higher risk of cardiovascular events and heart failure. Because this cardiometabolic connection is so strong, identifying high‑risk individuals early is essential to preventing progression of both conditions. A holistic approach—including guideline‑directed therapies that target blood pressure, glucose, and inflammation—can simultaneously lower the risk of heart disease and slow kidney decline. Newer treatments now allow clinicians to address both organs together, improving long‑term health outcomes.

In this interview, Allen J. Taylor, MD, FACC and Janani Rangaswami, MD examine “Cardiovascular-Kidney Therapies in CKD”.